We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
+38.67%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$144M
AUM Growth
+$17.4M
(+14%)
Cap. Flow
-$19.7M
Cap. Flow
% of AUM
-13.73%
Top 10 Holdings %
Top 10 Hldgs %
45.16%
Holding
104
New
9
Increased
14
Reduced
21
Closed
29
Avg Time Held
5.1
quarters
Top 10 Avg Time Held
3.3
quarters
Top 20 Avg Time Held
3.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tandem Diabetes Care
TNDM
|
+$3M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$2.63M |
| 3 |
Xenon Pharmaceuticals
XENE
|
+$2.32M |
| 4 |
BeOne Medicines Ltd
ONC
|
+$2.04M |
| 5 |
Ardelyx
ARDX
|
+$1.98M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$4.73M |
| 2 |
Rigel Pharmaceuticals
RIGL
|
+$4.32M |
| 3 |
Novavax
NVAX
|
+$4M |
| 4 |
Dermira, Inc.
DERM
|
+$3.05M |
| 5 |
NXTM
NxStage Medical Inc.
NXTM
|
+$2.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 79.26% |
| 2 | Miscellaneous | 20.74% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
VTAE
1
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
| $15M | 10.43% |
715,988
+55,800
| +8% | +$643K |
2015 Q3
4 quarters
|
|
|
CYNA
2
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
| $9.26M | 6.45% |
230,201
+7,842
| +4% | +$194K |
2015 Q2
5 quarters
|
|
3
AtriCure
ATRC
$2.89B
| $8.37M | 5.83% |
528,946
+15,000
| +3% | +$231K |
2013 Q2
13 quarters
|
|
|
NXTM
4
DELISTED
NxStage Medical Inc.
NXTM
| $5.96M | 4.15% |
238,509
-118,000
| -33% | -$2.75M |
2013 Q2
13 quarters
|
|
|
5
Tandem Diabetes Care
TNDM
$1.16B
| $5.55M | 3.86% |
72,429
+41,153
| +132% | +$3M |
2015 Q1
6 quarters
|
|
|
ALDR
6
DELISTED
Alder Biopharmaceuticals
ALDR
| $5.42M | 3.77% |
165,313
| – | – |
2015 Q3
4 quarters
|
|
7
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
| $4.27M | 2.98% |
66,068
+2,500
| +4% | +$141K |
2015 Q3
4 quarters
|
|
|
8
Xenon Pharmaceuticals
XENE
$3.33B
| $4.16M | 2.9% |
514,091
+300,000
| +140% | +$2.32M |
2015 Q3
4 quarters
|
|
|
AERI
9
DELISTED
Aerie Pharmaceuticals
AERI
| $3.47M | 2.41% |
91,869
-69,000
| -43% | -$1.52M |
2014 Q3
8 quarters
|
|
|
LOXO
10
DELISTED
Loxo Oncology, Inc
LOXO
| $3.41M | 2.37% |
130,222
+28,256
| +28% | +$739K |
2015 Q2
5 quarters
|
|
|
11
DELISTED
Dermira, Inc.
DERM
| $3.34M | 2.33% |
98,800
-94,842
| -49% | -$3.05M |
2016 Q1
2 quarters
|
|
12
Neurocrine Biosciences
NBIX
$13.7B
| $3.24M | 2.26% |
64,008
-11,495
| -15% | -$572K |
2016 Q1
2 quarters
|
|
13
Insulet
PODD
$9.58B
| $3.01M | 2.1% |
73,484
-18,680
| -20% | -$739K |
2013 Q2
13 quarters
|
|
|
TSRO
14
DELISTED
TESARO, Inc.
TSRO
| $2.96M | 2.06% |
29,500
-500
| -2% | -$46.7K |
2016 Q2
1 quarter
|
|
|
15
Ardelyx
ARDX
$806M
| $2.83M | 1.97% |
219,095
+189,095
| +630% | +$1.98M |
2016 Q1
2 quarters
|
|
|
16
BeOne Medicines Ltd
ONC
$39.5B
| $2.78M | 1.93% |
90,142
+70,142
| +351% | +$2.04M |
2016 Q1
2 quarters
|
|
17
Protagonist Therapeutics
PTGX
$8.96B
| $2.62M | 1.82% |
+123,804
| New | +$1.69M |
2016 Q3
0 quarters
|
|
|
FOMX
18
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $2.58M | 1.79% |
278,067
+85,500
| +44% | +$715K |
2015 Q4
3 quarters
|
|
|
AGTC
19
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $2.35M | 1.64% |
240,298
+73,106
| +44% | +$986K |
2015 Q1
6 quarters
|
|
20
Rocket Pharmaceuticals
RCKT
$252M
| $2.25M | 1.57% |
+59,309
| New | +$1.87M |
2016 Q3
0 quarters
|
|
21
Spyre Therapeutics
SYRE
$7.52B
| $2.25M | 1.56% |
14,016
| – | – |
2016 Q2
1 quarter
|
|
22
Tvardi Therapeutics
TVRD
$13.9M
| $2.23M | 1.55% |
7,418
| – | – |
2015 Q2
5 quarters
|
|
|
ISEE
23
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $2.15M | 1.5% |
+46,600
| New | +$2.63M |
2016 Q3
0 quarters
|
|
24
DELISTED
Radius Health, Inc.
RDUS
| $1.99M | 1.39% |
36,854
-746
| -2% | -$37.9K |
2016 Q1
2 quarters
|
|
|
IMMU
25
DELISTED
Immunomedics Inc
IMMU
| $1.84M | 1.28% |
566,796
-248,204
| -30% | -$694K |
2016 Q2
1 quarter
|
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q3 2016 Portfolio in Review
As of Q3 2016, DAFNA Capital Management held 104 positions worth $144M, up 14% from $126M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
DAFNA Capital Management withdrew a net $19.7M in Q3 2016, closing 29 positions and reducing 21 holdings. Its most notable exit was AbbVie, an estimated $4.73M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 85% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, DAFNA Capital Management opened a new position in IVERIC bio, Inc. Common Stock worth $2.15M.
- DAFNA Capital Management's largest Q3 2016 buy was IVERIC bio, Inc. Common Stock: 46,600 shares worth $2.15M.
- DAFNA Capital Management added most to Tandem Diabetes Care in Q3 2016, an estimated $3M increase.
- DAFNA Capital Management's biggest Q3 2016 reduction was Rigel Pharmaceuticals, cutting an estimated $4.32M.
- DAFNA Capital Management fully exited AbbVie in Q3 2016, selling an estimated $4.73M.
- DAFNA Capital Management's ten largest holdings make up 45% of its $144M portfolio in Q3 2016.
- DAFNA Capital Management opened 9 new positions and closed 29 in Q3 2016.
- DAFNA Capital Management's portfolio value rose 14% quarter-over-quarter to $144M.
Based on DAFNA Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.